Key terms
About GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GKOS news
Yesterday
9:49am ET
Micron upgraded, Peloton downgraded: Wall Street’s top analyst calls
Yesterday
9:49am ET
Micron upgraded, Peloton downgraded: Wall Street’s top analyst calls
Yesterday
4:59am ET
Glaukos upgraded to Buy from Hold at Jefferies
Yesterday
4:55am ET
Buy Rating on Glaukos with Strong Growth Prospects for iDose and MIGS Market Share
May 02
9:40am ET
Glaukos price target raised to $113 from $108 at Needham
May 02
9:16am ET
Glaukos price target raised to $125 from $120 at Truist
May 02
8:35am ET
Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)
May 02
8:18am ET
Glaukos Corporation: Strong Financials and Promising Pipeline Merit a Buy Rating
May 02
8:18am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Atricure (ATRC) and Glaukos (GKOS)
May 02
7:26am ET
Glaukos price target raised to $112 from $107 at BTIG
May 02
6:36am ET
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
May 02
6:17am ET
Glaukos price target raised to $110 from $103 at Wells Fargo
May 02
6:13am ET
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), American Well (AMWL) and Glaukos (GKOS)
May 02
5:55am ET
Buy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising iDose Prospects
May 01
4:24pm ET
Glaukos First-Quarter 2024 Financial Performance Overview
May 01
4:18pm ET
Glaukos sees FY24 revenue $357M-$365M, consensus $356.7M
May 01
4:17pm ET
Glaukos reports Q1 EPS (70c), consensus (57c)
Apr 15
7:35am ET
Glaukos price target raised to $107 from $102 at BTIG
Apr 11
7:01am ET
Glaukos price target raised to $100 from $85 at Mizuho
Apr 03
8:25am ET
Glaukos (GKOS) Gets a Buy from Stifel Nicolaus
Apr 03
7:07am ET
Glaukos receives permanent J-code for iDose TR
Apr 03
5:40am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Glaukos (GKOS) and Omnicell (OMCL)
Mar 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Mar 25
6:00am ET
Glaukos price target raised to $120 from $107 at Citi
Mar 22
7:07am ET
Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)
Feb 28
7:13am ET
Glaukos to Present Periodic Investor Updates Online
Feb 25
11:56pm ET
Glaukos Corporation: Hold Rating with Cautious Optimism Amidst iDose Launch and Reimbursement Uncertainties
Feb 22
8:34am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Moderna (MRNA) and Glaukos (GKOS)
Feb 22
8:03am ET
Piper Sandler Sticks to Its Buy Rating for Glaukos (GKOS)
Feb 22
7:27am ET
Buy Rating for Glaukos: A Comprehensive Analysis of Growth Drivers and Financial Stability
Feb 22
7:17am ET
Glaukos price target raised to $102 from $90 at BTIG
Feb 22
6:49am ET
Glaukos price target raised to $103 from $83 at Wells Fargo
No recent press releases are available for GKOS
GKOS Financials
Key terms
Ad Feedback
GKOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GKOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
